Trials / Completed
CompletedNCT00605241
A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of at least seven days between each session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK598809 | Drug |
Timeline
- Start date
- 2008-02-25
- Primary completion
- 2009-03-20
- Completion
- 2009-03-20
- First posted
- 2008-01-31
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00605241. Inclusion in this directory is not an endorsement.